Potentiation of MEKi efficacy by the estrogen receptor antagonist Fulvestrant in ERα-positive cancer cell lines.
收藏NIAID Data Ecosystem2026-03-07 收录
数据链接：
官方服务：
资源简介：
The predicted additive effect was determined by applying the Bliss additivity model§[25]. A greater than additive or synergistic interaction (observed effect exceeds the expected effect) was noted only in the ERα- expressing cell lines, SKOV3 and Ishikawa. Conversely, A2780, ERα-negative ovarian carcinoma cells exhibited antagonism between MEKi and fulvestrant. ¶As determined by SRB assay.
创建时间：
2013-02-04
